- Home
- DRMA vs QLGN Comparison
DRMA vs QLGN Comparison
Compare DRMA & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- QLGN
- Stock Information
- Founded
- DRMA 2014
- QLGN 1996
- Country
- DRMA United States
- QLGN United States
- Employees
- DRMA N/A
- QLGN N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- QLGN Health Care
- Exchange
- DRMA Nasdaq
- QLGN Nasdaq
- Market Cap
- DRMA 4.5M
- QLGN 4.7M
- IPO Year
- DRMA 2021
- QLGN N/A
- Fundamental
- Price
- DRMA $6.45
- QLGN $2.17
- Analyst Decision
- DRMA Strong Buy
- QLGN
- Analyst Count
- DRMA 1
- QLGN 0
- Target Price
- DRMA $3.00
- QLGN N/A
- AVG Volume (30 Days)
- DRMA 23.7K
- QLGN 2.6M
- Earning Date
- DRMA 08-11-2025
- QLGN 08-13-2025
- Dividend Yield
- DRMA N/A
- QLGN N/A
- EPS Growth
- DRMA N/A
- QLGN N/A
- EPS
- DRMA N/A
- QLGN N/A
- Revenue
- DRMA N/A
- QLGN N/A
- Revenue This Year
- DRMA N/A
- QLGN N/A
- Revenue Next Year
- DRMA N/A
- QLGN N/A
- P/E Ratio
- DRMA N/A
- QLGN N/A
- Revenue Growth
- DRMA N/A
- QLGN N/A
- 52 Week Low
- DRMA $5.74
- QLGN $2.00
- 52 Week High
- DRMA $37.90
- QLGN $13.43
- Technical
- Relative Strength Index (RSI)
- DRMA 43.91
- QLGN 25.05
- Support Level
- DRMA $5.94
- QLGN $2.46
- Resistance Level
- DRMA $7.33
- QLGN $2.98
- Average True Range (ATR)
- DRMA 0.63
- QLGN 0.47
- MACD
- DRMA -0.05
- QLGN -0.10
- Stochastic Oscillator
- DRMA 27.68
- QLGN 3.65
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.